Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06947291 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Name: Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors — clinical trial record (NCT06947291)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Started2025-06-04

View on ClinicalTrials.gov ↗

Amendment history

2025-09-02

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-04-30→confirmed 2025-06-04

Study sites0→1

2025-04-25

Original filing

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

42 trials monitored

See 1 trial at risk

Gastric Cancer

1,194 trials monitored

See 60 trials at risk

The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.

Trial Details

NCT Number	NCT06947291
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Enrollment	350 participants
Start Date	2025-06-04
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-10-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-08